Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C169918
http://purl.obolibrary.org/obo/NCIT_C169918
|
|---|---|
| Preferred Name | Disitamab Vedotin |
| Definitions |
An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2) and conjugated to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-HER2 ADC RC48, the antibody moiety targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, the cytotoxic agent induces tumor cell apoptosis, through an as of yet not publicly known mechanism. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2) and conjugated to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-HER2 ADC RC48, the antibody moiety targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, the cytotoxic agent induces tumor cell apoptosis, through an as of yet not publicly known mechanism. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. |
|---|---|
| prefLabel | Disitamab Vedotin
|
| label | Disitamab Vedotin
|
| NCI_META_CUI | CL1382403
|
| code | C169918
|
| prefixIRI | NCIT:C169918
|
| in_subset | |
| Preferred_Name | Disitamab Vedotin
|
| FDA_UNII_Code | RB3U3A1S27
|
| Contributing_Source | FDA
|
| Maps_To | Anti-HER2 Antibody-drug Conjugate RC48
|
| CAS_Registry | 2136633-23-1
|
| NCI_Drug_Dictionary_ID | 784850
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |